Burrows Scott L sold $223K of SYRE
Burrows Scott L (Chief Financial Officer) sold 3,100 shares of Spyre Therapeutics, Inc. (SYRE) at $72.06 ($0.22M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor whether this is part of a broader pattern of insider selling or isolated liquidity activity; absent other news, impact is typically sentiment/flow rather than fundamentals.
Market read
A routine 10b5-1 insider sale for SYRE; likely limited trading impact unless paired with other negative catalysts.
What to watch
The disclosure does not indicate intent beyond the pre-arranged plan; without additional context (e.g., multiple concurrent sales), signal is limited.
Background
SEC Form 4 reports insider transactions; open-market sales under a Rule 10b5-1 plan are pre-scheduled to comply with insider trading rules.
Ticker impact
Spyre Therapeutics CFO Scott L. Burrows sold 3,100 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/flow effects.
The filing is a Form 4 open-market sale and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive signal.
Market effects
Minimal; single-company insider sale with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
10b5-1 sales are often routine liquidity events; the market may overreact to the headline without new operational information.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the insider transaction disclosure; CFO sold shares under a pre-arranged 10b5-1 plan.
- insiderBurrows Scott L
Chief Financial Officer who executed the open-market sale.
